Negative

Cepheid Receives FDA Clearance for Xpert® Xpress GBS

Retrieved on: 
Monday, March 11, 2024
PCR, Obstetrics, Streptococcus, Rheumatic fever, EVP, INT, Risk, Cepheid variable, Antibiotic prophylaxis, Antimicrobial stewardship, Fungal infection, Genome, Woman, American College, GBS, Negative, ACOG, Infant, Food, Sintering

SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS). This next-generation test incorporates new dual targets in highly-conserved regions of the GBS genome to improve sensitivity and bacterial strain coverage. The test is designed for use on Cepheid's GeneXpert® systems.

Key Points: 
  • SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS).
  • Xpert Xpress GBS allows for the use of intrapartum direct PCR testing for women with unknown or unavailable antepartum GBS status.
  • With the capability of returning positive results as early as 30 minutes,2 Xpert Xpress GBS can provide real-time GBS status and inform decisions about empiric antibiotic prophylaxis if appropriate, to prevent GBS transmission during birth.
  • With Xpert Xpress GBS, Cepheid continues to provide fast, accurate, and reliable PCR solutions to facilitate evidence-based treatment and improved clinical care.

Advancing Skin Cancer Detection: American Academy of Dermatology Journal Publishes DermaSensor's Breakthrough Melanoma Detection Results From A Major, Multicenter Trial

Retrieved on: 
Wednesday, February 28, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Health Technology, Clinical Trials, Science, Medical Supplies, Practice Management, Health, VA Boston Healthcare System, Skin cancer, Melanoma, NPV, Principal, Physician, FDA, Integral, Hospital, Assessment, Skin, Negative, Patient, Journal, Cone Health Women's Hospital, Harvard Medical School, American Academy, Medical device

In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.

Key Points: 
  • In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.
  • For a positive device result of “Investigate Further”, a 1-10 score is also provided to indicate the degree of similarity to malignant lesions.
  • The study found that the likelihood of melanoma for these positive results ranged from 10.3% for low scores (i.e., 1-3) to 47.4% for high scores (i.e., 8-10).
  • This automated, objective device can help in the fight against skin cancer, and the DermaSensor team is dedicated to making a meaningful contribution to its detection and prevention."

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

Retrieved on: 
Wednesday, January 3, 2024
IVUS, Partnership, Risk, CCTA, Physician, FDA, Plaque, CAD, PET, Health, Negative, ACC, Hospital, SCCT, Medicare, Artificial intelligence, EKG, Foreign policy, Growth, Patient, Diagnosis, SPECT

MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis.
  • HeartFlow’s FFRCT provides clear insights into each patient’s condition with a patient-specific visual model of the heart’s blood flow.
  • Since its inception, HeartFlow has been committed to building a new standard of care for people at risk of heart disease.
  • “We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMapTM Analysis.

This Week in People & Culture News: 11 Stories You Need to See

Retrieved on: 
Friday, December 1, 2023
PR Newswire, Dream, Negative

NEW YORK, Dec. 1, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering different cultural groups stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • A roundup of the week's most newsworthy culture press releases from PR Newswire, including campaigns to boost women's body confidence and support Black and Latinx small businesses.
  • NEW YORK, Dec. 1, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
  • To help journalists covering different cultural groups stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.
  • The list below includes the headline (with a link to the full text) and an excerpt from each story.

Fortified Wine Market to increase by USD 5.2 billion between 2022 to 2027 | The rising consumption rate of wine is notably driving the fortified wine market.- Technavio

Retrieved on: 
Thursday, September 14, 2023
History, USD, Free, Campari Group, Distiller, Contratto, Growth, Negative, PDF, Wine, Bottled water, Geography

NEW YORK, Sept. 14, 2023 /PRNewswire/ -- The fortified wine market size is expected to grow by USD 5.2 billion from 2022 to 2027, according to Technavio.

Key Points: 
  • NEW YORK, Sept. 14, 2023 /PRNewswire/ -- The fortified wine market size is expected to grow by USD 5.2 billion from 2022 to 2027, according to Technavio.
  • The rising consumption rate of wine is notably driving the fortified wine market.
  • Its unique characteristics and high demand among wine enthusiasts worldwide cause sherry to hold a significant position in the global fortified wine market.
  • The fortified wine market is fragmented, and the companies are deploying organic and inorganic growth strategies to compete in the market.

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, General Health, Biometrics, Health, Health Technology, Intervention, Probability, Medical University of South Carolina, University, University of Pennsylvania Health System, ATS, ORACLE, Cancer, Lung cancer, Vanderbilt University Medical Center, Medical school, Diagnosis, MS, American Thoracic Society, International Conference on Information Systems Security and Privacy, Patient, Assessment, Negative, Integration, Convention center, Conference, Medical imaging, Biomarker

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.
  • The meeting will take place May 19-24, 2023, in Washington, DC.
  • Data from the abstract titled, Assessment of an Integrated Classifier’s Ability to Distinguish Benign from Malignant Nodules: Subgroup Analysis of the ORACLE Registry, presented by Dr. K. J.
  • Both poster presentations will occur during ATS discussion Session C99 – Advances in Biomarkers Across the Lung Cancer Continuum.

California Jazz Conservatory Salutes 25 Years of Accomplishments by CJC Grads and Jazzschool Alums; Small Classes, Individual Attention, Focus on Jazz, Credited for Success

Retrieved on: 
Tuesday, November 22, 2022
Common, Student, Harvard University, Platinum, California Institute of the Arts, Faculty, National Endowment for the Arts, Silver, Attention, Performing arts, White, White House, Participation, Rockefeller Foundation, CJC, United Nations, Curriculum, Alien Boy, California Arts Council, NBC, Recognition, American Symphony, Multimedia, DownBeat, Negative, First Place, MFA, Nightclub, The arts, Music, Carnegie Hall, California Jazz Conservatory

With performance at the center of the CJC curriculum, alumni continue to advance their careers on the stage and in the recording studio.

Key Points: 
  • With performance at the center of the CJC curriculum, alumni continue to advance their careers on the stage and in the recording studio.
  • One outstanding success story in point is Venezuelan music specialist, Jackie Rago, a longtime teacher and student at the Jazzschool, who recently appeared with John Batiste, performing his "American Symphony," in Carnegie Hall.
  • We salute our CJC grads and Jazzschool alums for their accomplishments."
  • For more information about the CJC, please contact Paul Fingernote at 831-373-3343or [email protected] .

Cepheid Introduces Xpert GBS LB XC

Retrieved on: 
Wednesday, November 16, 2022
Genome, ACOG, Negative, Cepheid variable, Molecular biology, Cancer, Marketing, EVP, Infection, GBS, Solution, Sintering

SUNNYVALE, Calif., Nov. 16, 2022 /PRNewswire/ -- Cepheid today announced the availability of Xpert® GBS LB XC (extended coverage), a molecular diagnostic test for qualitative detection of Group B Streptococcus (GBS) using enriched Lim broth cultures of patient samples. Xpert GBS LB XC builds upon the success of Xpert GBS LB which was launched in 2012. The next-generation test is now available and will begin shipping to US customers in November.

Key Points: 
  • SUNNYVALE, Calif., Nov. 16, 2022 /PRNewswire/ -- Cepheid today announced the availability of Xpert GBS LB XC (extended coverage), a molecular diagnostic test for qualitative detection of Group B Streptococcus (GBS) using enriched Lim broth cultures of patient samples.
  • Xpert GBS LB XC builds upon the success of Xpert GBS LB which was launched in 2012.
  • Xpert GBS LB XCincorporates new dual targets in highly conserved regions of the GBS genome to improve coverage and performance.
  • Xpert GBS LB XC is clearedto be used for screening of pregnant females, in line with ACOG guidance for GBS testing.

Aehr Announces New Advanced Testing Capabilities on its FOX-P™ Wafer Level Test & Burn-in Systems for Silicon Carbide and Gallium Nitride Technologies

Retrieved on: 
Thursday, October 6, 2022
Electric Bond and Share Company v. Securities and Exchange Commission, Negative, Traction, Silicon carbide, Energy Independence and Security Act of 2007, Logic, Memory, VTH, 2D, Automotive industry, MOSFET, AEHR, Securities Exchange Act of 1934, NASDAQ, Bias, Silicon, Mobility, 3D, Contactor, Security (finance), Gallium nitride, Securities Act of 1933, Technology, Form 10-K, High voltage, Aligner, Percussion section, Â, CEO, Carrier, ABTS, GLOBE, Forward-looking statement, FOX, Solution, Engineering, Semiconductor, Ceramic, Electronic component

The BVCM can supply gate bias voltage to more than 3,000 die per wafer while capable of monitoring individual die performance.

Key Points: 
  • The BVCM can supply gate bias voltage to more than 3,000 die per wafer while capable of monitoring individual die performance.
  • The BVCM, in combination with Aehrs proprietary WaferPak full-wafer Contactors, deliver a unique capability benefitting power silicon carbide diodes and MOSFETs and both E-mode and D-mode gallium nitride power MOSFET manufacturers.
  • A full wafer HTRB stress test on silicon carbide or gallium nitride technology can be applied up to 2,000 volts in a single touchdown.
  • Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in semiconductor devices in wafer level, singulated die, and package part form, and has installed over 2,500 systems worldwide.

Mobile Roaming Revenues From Consumer & IoT Connections to Reach $30 Billion in 2023: Kaleido Intelligence

Retrieved on: 
Wednesday, July 13, 2022
Networks, 5G, Mobile, Wireless, Technology, Telecommunications, IOT, Intelligence, Travel, COVID, Policy, Negative, Kaleido Star, CAGR, Growth, Research, Industry, Tourism, Mobile phone

Although international travel volume in H1 2022 remained lower than pre-COVID levels, recovery prospects are significantly better than in 2021.

Key Points: 
  • Although international travel volume in H1 2022 remained lower than pre-COVID levels, recovery prospects are significantly better than in 2021.
  • While the total market for IoT roaming is set to be dampened somewhat due to these market influences, roaming connections are nevertheless expected to outpace the overall cellular IoT market in terms of growth.
  • Kaleido predicts that roaming IoT connections are forecast to reach nearly 940 million in 2027, up from 297 million in 2021, growing at a CAGR of 22% between 2022 and 2027.
  • Kaleido Intelligence is the only research company addressing mobile roaming in its entirety, covering: